Policy & Regulation
Nona Biosciences agrees research collaboration with Medical University of Vienna to advance fully human antibody development for infectious diseases
23 July 2026 - Global biotechnology company Nona Biosciences, a wholly owned subsidiary of HBM Holding Limited (HKEX:02142), announced on Wednesday a research collaboration with the Medical University...
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
23 July 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhib...
Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial
22 July 2026 - US biopharmaceutical company Greenwich LifeSciences, Inc. (NASDAQ: GLSI) said on Wednesday it has received regulatory clearance to extend its Phase III FLAMINGO-01 trial into the United...
Arrowhead reports positive Phase 3 results for plozasiran in severe hypertriglyceridaemia
22 July 2026 - Pharmaceutical company Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with sever...
Ipsen completes Memo Therapeutics acquisition to strengthen rare disease pipeline
22 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that it has completed the acquisition of Memo Therapeutics AG, adding late-stage asset pot...
Hugel Aesthetics expands US presence
22 July 2026 - Australian pharmaceutical company Hugel Aesthetics announced on Tuesday a major expansion of its US business as part of its long-term growth strategy.The expansion includes the launch o...